Retatrutide is an investigational multi-receptor peptide agonist that combines activity at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a next-generation metabolic therapy designed to leverage the synergistic effects of these three hormonal pathways to improve energy expenditure, insulin sensitivity, and appetite control. Mechanistically, GLP-1 and GIP agonism enhances glucose-dependent insulin secretion, delays gastric emptying, and reduces food intake, while glucagon receptor activation increases lipolysis and energy expenditure. This triple-action…
Retatrutide is an investigational multi-receptor peptide agonist that combines activity at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a next-generation metabolic therapy designed to leverage the synergistic effects of these three hormonal pathways to improve energy expenditure, insulin sensitivity, and appetite control. Mechanistically, GLP-1 and GIP agonism enhances glucose-dependent insulin secretion, delays gastric emptying, and reduces food intake, while glucagon receptor activation increases lipolysis and energy expenditure. This triple-action…
